BiotechTube

Filgrastim

Pre-clinicalTerminated
0 watching 0 views this week💤 Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Graft-Versus-Host Disease

Conditions

Graft-Versus-Host Disease

Trial Timeline

Feb 1, 2003 → Sep 1, 2008

NCT ID
NCT00501228

About Filgrastim

Filgrastim is a pre-clinical stage product being developed by Amgen for Graft-Versus-Host Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00501228. Target conditions include Graft-Versus-Host Disease.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (3)

NCT IDPhaseStatus
NCT00002126Phase 2Completed
NCT00115128Pre-clinicalCompleted
NCT00501228Pre-clinicalTerminated

Competing Products

20 competing products in Graft-Versus-Host Disease

See all competitors
ProductCompanyStageHype Score
AlefaceptAstellas PharmaPhase 2
52
EQ001 + EQ001 PlaceboBioconPhase 1/2
41
SHR0302Jiangsu Hengrui MedicinePhase 1
33
Prednisone + Jakavi(ruxolitinib) + PrednisoneNovartisPhase 2
52
PredEverNovartisPhase 2
52
Lifitegrast 5% Ophthalmic Solution + PlaceboNovartisPhase 1
33
LBH589 + MethylprednisoloneNovartisPhase 2
52
Panobinostat (LBH589)NovartisPhase 1/2
41
AMG 592AmgenPhase 1
32
AMG 592AmgenPhase 1
32
BMS-986004 + Sirolimus + TacrolimusBristol Myers SquibbPhase 1
32
Belumosudil (KD025)SanofiPhase 2
51
Belumosudil 200 mg QD + Belumosudil 200 mg BID + Belumosudil 400 mg QDSanofiPhase 2
51
AAT + PlaceboCSLPhase 2/3
64
Ruxolitinib + MethylprednisoloneIncytePhase 2
49
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
74
Itacitinib + CorticosteroidsIncytePhase 1/2
38
RuxolitinibIncytePre-clinical
20
Itacitinib + CorticosteroidIncytePhase 1
30
INCA034176IncytePhase 1/2
38

Other Products from Amgen

Aranesp®Approved
84
PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84